Anti-Mouse TIGIT Polyclonal Antibody (MS739014)

Name: Anti-Mouse TIGIT Polyclonal Antibody
Brand: abinScience
SKU: MS739014
Price: 168 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

MS739014

Reactividad de especies

Mouse

Aplicaciones

ELISA, IHC, WB

Especie huésped

Rabbit

Clonalidad

Polyclonal

Isotipo

IgG

Inmunógeno

E. coli - derived recombinant Mouse TIGIT (Gly28-Glu131).

Objetivo

T-cell immunoreceptor with Ig and ITIM domains, TIGIT, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, VSIG9, VSTM3

Nivel de endotoxinas

Please contact with the lab for this information.

Pureza

>90% as determined by SDS-PAGE.

Purificación

Purified by antigen affinity column.

Número de acceso

P86176

Forma

Liquid

Buffer de almacenamiento

0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a ~26 kDa protein. Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. TIGIT is the therapeutic target of tiragolumab (clinical).

Nota

For research use only.

Imágenes

Referencias

Datasheet